New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

Life-course analysis sheds light on how movement patterns influence brain resilience, giving clinicians new context for counseling about dementia prevention.

Topics include new findings on oral acromegaly therapy, alcohol and dementia risk, tirzepatide in youth T2D, precision mood care, and LARC outcomes.

FDA approves Dexcom Smart Basal, a groundbreaking CGM-integrated insulin dosing optimizer, enhancing diabetes management for adults with Type 2 diabetes.

Eisai and Acumen Therapeutics will present new data in areas including long-term outcomes, brain delivery strategies, and early-stage Alzheimer disease.

Real-world data from 20 000 patients demonstrate significantly higher adherence rates with Shield blood test vs colonoscopy and stool-based screening methods.

Deep TMS becomes first FDA-cleared brain stimulation therapy for adolescents with treatment-resistant depression and is now available for ages 15-86 for MDD treatment.

Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.

Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.

TMS: Harvard's Caroline Mitchell, MD, MPH, questions the direction of genitourinary syndrome research priorities and reflects on FDA's removal of HRT warnings.

Study author Daniel Jiang, MD, PhD, discusses data linking hormone therapy to increased autoimmune disease risk in postmenopausal women and clinical implications.